NDA is a world leading regulatory drug & device development consultancy, supporting companies with their regulatory, pharmacovigilance, quality and strategic communication challenges across the US and Europe, from concept to commercialization. In 2020 the NDA team supported 1 in 5 of the medicinal products approved by the FDA and 42% of the medicinal products approved in Europe. To learn more, visit www.ndareg.com

Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making. For more information, please visit nucleai.ai

Oncimmune, a global leader in immunodiagnostics is focused on autoantibody profiling in immuno-oncology, autoimmune and infectious diseases. Through ImmunoINSIGHTS profiling services, we provide clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy. The headquarter is based in UK and also operates in Germany and USA.

Outpace Bio is pioneering the era of curative cell therapies with built-for-purpose function powered by protein design. With an initial focus on oncology, the Company is creating technologies that solve efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive potent and persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the specificity and safety necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. Outpace is based in Seattle, Washington. To learn more, visit outpacebio.com.

Palleon is a clinical-stage company pioneering drug development in glyco-immunology, a transformative field that shows that the immune system can be dysregulated by glycans. To learn more, please visit www.palleonpharma.com

PathAI is focused on transforming pathology and diagnostics through innovative digital solutions. By combining advanced machine learning with deep pathology expertise, PathAI’s solutions accelerate biomarker discovery, drug development, improve patient outcomes, and support data-driven decision-making at every stage of clinical and diagnostic workflows. Together, we are redefining the future of pathology, enabling pathologists and scientists to lead the charge in modern healthcare. For more information, visit http://pathai.com/

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing laboratories globally and is currently the sole sequencing provider to the VA MVP. To enable cancer and population sequencing, the Personalis Clinical Laboratory is built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Presage’s mission is understanding the complexity of drug response in the tumor microenvironment. Our CIVO® platform delivers trackable microdoses of multiple drugs and drug combinations directly into intact patient tumors to generate deep, spatial biology insights. CIVO’s unique approach to oncology clinical investigation informs and de-risks oncology drug development.

RefleXion transforms radiopharmaceuticals from diagnosing cancer to actively guiding delivery of external-beam radiotherapy by leveraging individual tumor biology. Designated an FDA Breakthrough Device, RefleXion’s SCINTIX biology-guided radiotherapy automates targeting and motion management to overcome long-standing barriers preventing definitive radiotherapy for metastatic disease. In strategic collaborations with radiopharmaceutical companies, RefleXion is co-developing and co-commercializing disease-specific radiotracers for difficult to treat late-stage cancers. To learn more, please visit www.reflexion.com

Rho is a global, privately held CRO headquartered in Research Triangle Park, NC and provides a full range of drug development services. For 39 years, Rho has been a trusted partner to some of the most innovative pharmaceutical and biotechnology companies, maximizing ROI by delivering consistent and efficient programs.
Experience, Rho. To learn more, please visit www.rhoworld.com

SIRPant Immunotherapeutics utilizes specifically engineered autologous macrophages (SIRPant-M) to generate polyclonal T cell and antibody responses in vivo that are tumor neo-antigen directed. Phase I trials for treatment of NHL initiate in Q4 2023, with an additional IND for treatment of solid tumors submitted Nov 2023. To learn more, please visit www.sirpantimmunotx.com.